Scinovex
articleTop 1% cited

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

Ophthalmology · 2008 · Vol. 116(1) · pp. 57–65.e5
David M. BrownMark MichelsPeter K. KaiserJeffrey S. HeierJudy P. SyTsontcho Ianchulev
Retinal Diseases and TreatmentsRetinal Imaging and AnalysisRetinal and Optic ConditionsVerteporfinMedicineMacular degenerationPhotodynamic therapyRanibizumabOphthalmologyAntiangiogenic therapyOptometryChoroidal neovascularizationSurgery

MeSH terms

RanibizumabVerteporfinAgedAged, 80 and overAntibodies, MonoclonalDouble-Blind MethodFemaleFluorescein AngiographyHumansInjectionsIntraocular PressureMacular DegenerationMaleMiddle AgedPhotochemotherapy

Funding

  • Genentech
  • Novartis Pharma
Citations
1,312
FWCI
50.07
field-weighted impact
References
13
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.